GlycoMimetics, Inc. (GLYC)
Market Cap | 21.28M |
Revenue (ttm) | 10,000 |
Net Income (ttm) | -39.74M |
Shares Out | 64.48M |
EPS (ttm) | -0.62 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 3,459,408 |
Open | 0.350 |
Previous Close | 0.379 |
Day's Range | 0.310 - 0.369 |
52-Week Range | 0.140 - 3.530 |
Beta | 1.84 |
Analysts | Hold |
Price Target | 12.00 (+3,536.36%) |
Earnings Date | Nov 13, 2024 |
About GLYC
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protei... [Read more]
Financial Performance
In 2023, GlycoMimetics's revenue was $10,000, a decrease of -86.67% compared to the previous year's $75,000. Losses were -$36.90 million, -20.97% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for GLYC stock is "Hold." The 12-month stock price forecast is $12.0, which is an increase of 3,536.36% from the latest price.
News
Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024
Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors WALTHAM, Mass. , Nov. 12, 2024 /PRNewswire/ -- Crescent Biopharma, Inc...
GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been...
GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of GlycoMimetics,...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders
NEW YORK , Oct. 29, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...
GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (NASDAQ: GLYC) announced today it has entered into an acquisition agreement with Crescent Biopharma, Inc. (“Crescent”), a privately held biotechnol...
GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory dis...
GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript
GlycoMimetics, Inc. (NASDAQ:GLYC) Corporate Update Call May 6, 2024 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - CEO Edwin Rock - Chief Medical Officer ...
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...
GlycoMimetics: Is No News Bad News?
GlycoMimetics is a biotech company focusing on developing a targeted therapy for acute myeloid leukemia. GLYC's lead candidate, uproleselan, has shown promising results in early-stage clinical trials ...
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, ...
GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript
GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...
GlycoMimetics Can Become A Game Changer In Blood Cancers
GlycomiMetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies. AML is a disease with a poor p...
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2023 full year financial results on We...
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 44th Annual Heal...
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the Compensation Committee of the Company's Board of Directors approved the grant on February 6,...
GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real
GlycoMimetics is developing molecules that target specific carbohydrate groups in the treatment of cancer. The company's most advanced project, Uproleselan, has recently shown promising results in a p...
GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...
GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthca...
GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call Transcript
GlycoMimetics, Inc. (NASDAQ:GLYC) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - Chief Executive Officer...
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...